RISANKIZUMAB vs RISDIPLAM: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
RISANKIZUMAB vs RISDIPLAM: Safety Overview
| Metric | RISANKIZUMAB | RISDIPLAM |
|---|---|---|
| Total FAERS Reports | 2,642 | 3,619 |
| Deaths Reported | 41 | 336 |
| Death Rate | 1.6% | 9.3% |
| Hospitalizations | 439 | 719 |
| Average Patient Age | 52.1 yrs | 21.8 yrs |
| % Female Patients | 51.3% | 55.2% |
| FDA Approval Date | N/A | Aug 7, 2020 |
| Manufacturer | AbbVie Inc. | Genentech, Inc. |
| Route | SUBCUTANEOUS | ORAL |
| Marketing Status | N/A | Prescription |